{"id":"teriparatide-rdna-origin","safety":{"commonSideEffects":[{"rate":"~10-15%","effect":"Injection site reactions (erythema, pain, swelling)"},{"rate":"~8-10%","effect":"Nausea"},{"rate":"~5-7%","effect":"Dizziness"},{"rate":"~5-7%","effect":"Headache"},{"rate":"~3-5%","effect":"Leg cramps"},{"rate":"~1-3%","effect":"Hypercalcemia"}]},"_chembl":{"chemblId":"CHEMBL1201549","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Teriparatide mimics the action of endogenous parathyroid hormone by binding to PTH1 receptors on osteoblasts, promoting bone anabolism and increasing bone mineral density. Unlike continuous PTH exposure (which causes bone loss), intermittent PTH administration preferentially stimulates bone formation over resorption, leading to net increases in bone mass and strength.","oneSentence":"Teriparatide is a recombinant human parathyroid hormone (PTH 1-34) that stimulates osteoblasts to increase bone formation and remodeling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:31.604Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women at high risk of fracture"},{"name":"Osteoporosis in men at high risk of fracture"},{"name":"Glucocorticoid-induced osteoporosis"}]},"trialDetails":[{"nctId":"NCT04589819","phase":"PHASE4","title":"Fracture Recovery for Returning to Duty (Teriparatide STRONG)","status":"ENROLLING_BY_INVITATION","sponsor":"University of South Carolina","startDate":"2022-12-08","conditions":"Stress Fracture of Tibia or Fibula","enrollment":183},{"nctId":"NCT01945788","phase":"PHASE4","title":"Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo","status":"UNKNOWN","sponsor":"Bio Sidus SA","startDate":"2013-06","conditions":"Postmenopausal Osteoporosis With Pathological Fracture","enrollment":110},{"nctId":"NCT00532545","phase":"PHASE4","title":"Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-04","conditions":"Osteoporosis, Post-Menopausal","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Teriparatide (rDNA origin)","genericName":"Teriparatide (rDNA origin)","companyName":"Bio Sidus SA","companyId":"bio-sidus-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Teriparatide is a recombinant human parathyroid hormone (PTH 1-34) that stimulates osteoblasts to increase bone formation and remodeling. Used for Osteoporosis in postmenopausal women at high risk of fracture, Osteoporosis in men at high risk of fracture, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}